KR20160038057A - 글라티라머 아세테이트를 포함하는 약제 - Google Patents
글라티라머 아세테이트를 포함하는 약제 Download PDFInfo
- Publication number
- KR20160038057A KR20160038057A KR1020167006001A KR20167006001A KR20160038057A KR 20160038057 A KR20160038057 A KR 20160038057A KR 1020167006001 A KR1020167006001 A KR 1020167006001A KR 20167006001 A KR20167006001 A KR 20167006001A KR 20160038057 A KR20160038057 A KR 20160038057A
- Authority
- KR
- South Korea
- Prior art keywords
- patient
- medicament
- glatiramer acetate
- injection site
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims abstract description 55
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims abstract description 52
- 229960003776 glatiramer acetate Drugs 0.000 title claims abstract description 52
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 50
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 50
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims description 79
- 230000003902 lesion Effects 0.000 claims description 70
- 201000006417 multiple sclerosis Diseases 0.000 claims description 61
- 238000007920 subcutaneous administration Methods 0.000 claims description 43
- 238000002347 injection Methods 0.000 claims description 28
- 239000007924 injection Substances 0.000 claims description 28
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 26
- 230000001965 increasing effect Effects 0.000 claims description 24
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims description 18
- 210000004556 brain Anatomy 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 16
- 229940071643 prefilled syringe Drugs 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000003251 Pruritus Diseases 0.000 claims description 12
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 12
- 230000001186 cumulative effect Effects 0.000 claims description 12
- 206010022095 Injection Site reaction Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 208000024806 Brain atrophy Diseases 0.000 claims description 10
- 206010008479 Chest Pain Diseases 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 208000024780 Urticaria Diseases 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 230000007803 itching Effects 0.000 claims description 9
- 206010015150 Erythema Diseases 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 206010012735 Diarrhoea Diseases 0.000 claims description 7
- 208000032843 Hemorrhage Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 230000009266 disease activity Effects 0.000 claims description 7
- 231100000321 erythema Toxicity 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 206010006784 Burning sensation Diseases 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 206010051290 Central nervous system lesion Diseases 0.000 claims description 5
- 206010028813 Nausea Diseases 0.000 claims description 5
- 206010042674 Swelling Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000008693 nausea Effects 0.000 claims description 5
- 206010037844 rash Diseases 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- 208000006820 Arthralgia Diseases 0.000 claims description 4
- 206010003591 Ataxia Diseases 0.000 claims description 4
- 208000000059 Dyspnea Diseases 0.000 claims description 4
- 206010013975 Dyspnoeas Diseases 0.000 claims description 4
- 208000010201 Exanthema Diseases 0.000 claims description 4
- 208000005577 Gastroenteritis Diseases 0.000 claims description 4
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 4
- 206010022078 Injection site inflammation Diseases 0.000 claims description 4
- 206010030124 Oedema peripheral Diseases 0.000 claims description 4
- 208000003435 Optic Neuritis Diseases 0.000 claims description 4
- 206010033557 Palpitations Diseases 0.000 claims description 4
- 206010067868 Skin mass Diseases 0.000 claims description 4
- 208000001871 Tachycardia Diseases 0.000 claims description 4
- 206010072731 White matter lesion Diseases 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 230000001269 cardiogenic effect Effects 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 208000032625 disorder of ear Diseases 0.000 claims description 4
- 201000005884 exanthem Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 230000035900 sweating Effects 0.000 claims description 4
- 230000006794 tachycardia Effects 0.000 claims description 4
- 208000000044 Amnesia Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 206010008469 Chest discomfort Diseases 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 claims description 3
- 208000003164 Diplopia Diseases 0.000 claims description 3
- 206010014020 Ear pain Diseases 0.000 claims description 3
- 206010016059 Facial pain Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 206010067142 Immediate post-injection reaction Diseases 0.000 claims description 3
- 206010022067 Injection site haemorrhage Diseases 0.000 claims description 3
- 206010022081 Injection site mass Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 206010040030 Sensory loss Diseases 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 230000037007 arousal Effects 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 230000007844 axonal damage Effects 0.000 claims description 3
- 208000034158 bleeding Diseases 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 claims description 3
- 210000005013 brain tissue Anatomy 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 238000011010 flushing procedure Methods 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 208000013465 muscle pain Diseases 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 230000001568 sexual effect Effects 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 201000004569 Blindness Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 206010010947 Coordination abnormal Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 206010016334 Feeling hot Diseases 0.000 claims description 2
- 206010060800 Hot flush Diseases 0.000 claims description 2
- 206010022086 Injection site pain Diseases 0.000 claims description 2
- 206010022107 Injection site urticaria Diseases 0.000 claims description 2
- 206010022998 Irritability Diseases 0.000 claims description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 208000031513 cyst Diseases 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 208000011318 facial edema Diseases 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 208000028756 lack of coordination Diseases 0.000 claims description 2
- 208000018883 loss of balance Diseases 0.000 claims description 2
- 230000004461 rapid eye movement Effects 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims 3
- 206010022061 Injection site erythema Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000003007 myelin sheath Anatomy 0.000 claims 1
- 230000009711 regulatory function Effects 0.000 claims 1
- 239000000902 placebo Substances 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 33
- 208000024891 symptom Diseases 0.000 description 24
- 238000012216 screening Methods 0.000 description 21
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 19
- 208000017547 Ectodermal dysplasia-syndactyly syndrome Diseases 0.000 description 15
- 238000001990 intravenous administration Methods 0.000 description 11
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 230000000116 mitigating effect Effects 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 229910052688 Gadolinium Inorganic materials 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 210000004884 grey matter Anatomy 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 229940038717 copaxone Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000009251 neurologic dysfunction Effects 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 208000015015 neurological dysfunction Diseases 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022079 Injection site irritation Diseases 0.000 description 1
- 206010022093 Injection site pruritus Diseases 0.000 description 1
- 206010053425 Injection site swelling Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 101000999374 Rattus norvegicus Interferon-related developmental regulator 1 Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WCIDIJQCEUODDY-UHFFFAOYSA-N chloro(dimethyl)sulfanium Chemical compound C[S+](C)Cl WCIDIJQCEUODDY-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004370 retrospective diagnosis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27468709P | 2009-08-20 | 2009-08-20 | |
| US61/274,687 | 2009-08-20 | ||
| US33761210P | 2010-02-11 | 2010-02-11 | |
| US61/337,612 | 2010-02-11 | ||
| PCT/US2010/002283 WO2011022063A1 (en) | 2009-08-20 | 2010-08-19 | Low frequency glatiramer acetate therapy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147012452A Division KR20140061559A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177031069A Division KR20170123354A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160038057A true KR20160038057A (ko) | 2016-04-06 |
Family
ID=43605835
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167006001A Ceased KR20160038057A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
| KR1020127007115A Ceased KR20120090044A (ko) | 2009-08-20 | 2010-08-19 | 낮은 빈도의 글라티라머 아세테이트 치료법 |
| KR1020147012452A Ceased KR20140061559A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
| KR1020177031069A Ceased KR20170123354A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127007115A Ceased KR20120090044A (ko) | 2009-08-20 | 2010-08-19 | 낮은 빈도의 글라티라머 아세테이트 치료법 |
| KR1020147012452A Ceased KR20140061559A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
| KR1020177031069A Ceased KR20170123354A (ko) | 2009-08-20 | 2010-08-19 | 글라티라머 아세테이트를 포함하는 약제 |
Country Status (34)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US8077333B2 (en) * | 2002-09-09 | 2011-12-13 | Canon Kabushiki Kaisha | Printing control apparatus and printing control method |
| HUE031282T2 (hu) | 2009-08-20 | 2017-06-28 | Yeda Res & Dev | Alacsony gyakoriságú glatiramer acetát terápia |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| NZ703122A (en) | 2010-10-11 | 2016-06-24 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| KR20140101730A (ko) | 2011-10-10 | 2014-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성 |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| EA201591251A1 (ru) * | 2013-01-04 | 2016-05-31 | Тева Фармасьютикал Индастриз Лтд. | Характеризация лекарственного продукта, родственного ацетату глатирамера |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CN103641897B (zh) * | 2013-11-27 | 2017-01-04 | 深圳翰宇药业股份有限公司 | 一种合成醋酸格拉替雷的方法 |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| WO2015195605A1 (en) * | 2014-06-17 | 2015-12-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of glatiramer acetate by oral patches |
| CN104844697B (zh) * | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | 醋酸格拉替雷的制备方法 |
| US9155775B1 (en) * | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| DK3506921T3 (da) | 2016-08-31 | 2023-07-31 | Mapi Pharma Ltd | Depotsystemer, der omfatter glatirameracetat |
| CN110087530A (zh) | 2016-12-07 | 2019-08-02 | 普罗根尼蒂公司 | 胃肠道检测方法、装置和系统 |
| US11167003B2 (en) | 2017-03-26 | 2021-11-09 | Mapi Pharma Ltd. | Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems |
| JP2020525459A (ja) * | 2017-06-26 | 2020-08-27 | アンスティテュ・パストゥール | Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置 |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
| CA3145269A1 (en) | 2019-07-22 | 2021-01-28 | Michel BURCKLEN | Use of ponesimod for the treatment of multiple sclerosis |
| KR102519053B1 (ko) | 2021-02-08 | 2023-04-06 | 건국대학교 산학협력단 | 염산가스의 농도 측정을 위한 수분 전처리 시스템 |
| KR102519054B1 (ko) | 2021-03-12 | 2023-04-06 | 건국대학교 산학협력단 | 나피온 드라이어와 수분 전처리장치의 결합시스템 |
| EP4415699A1 (en) * | 2021-10-11 | 2024-08-21 | Laboratoires Juvise Pharmaceuticals | Methods of treating multiple sclerosis |
| WO2023061935A1 (en) | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| DE3673317D1 (de) | 1985-10-11 | 1990-09-13 | Duphar Int Res | Automatische spritze. |
| US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| US6454746B1 (en) | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| IL140592A0 (en) | 1998-07-23 | 2002-02-10 | Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| EP2090583B1 (en) | 1998-09-25 | 2011-07-13 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| EP1128839A4 (en) | 1998-11-12 | 2002-10-09 | Yeda Res & Dev | PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD |
| EP2110138A1 (en) | 1999-08-27 | 2009-10-21 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| HK1054507B (zh) | 2000-01-20 | 2008-10-31 | 耶达研究及发展有限公司 | 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途 |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| ATE329608T1 (de) | 2000-02-18 | 2006-07-15 | Yeda Res & Dev | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung |
| JP2003535118A (ja) | 2000-06-05 | 2003-11-25 | テバ ファーマシューティカル インダストリーズ リミティド | 中枢神経系障害の治療におけるグラチラマーアセテート（共重合体１）の使用 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| EP1294390B1 (en) | 2000-06-07 | 2006-01-04 | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| MXPA04005433A (es) | 2001-12-04 | 2004-10-11 | Teva Pharma | Proceso para la medicion de la potencia de acetato de glatiramero. |
| AU2003283152A1 (en) | 2002-11-13 | 2004-06-03 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| WO2004047893A1 (de) | 2002-11-25 | 2004-06-10 | Tecpharma Licensing Ag | Autoinjektor mit rückstellbarer auslösesicherung |
| US7274347B2 (en) | 2003-06-27 | 2007-09-25 | Texas Instruments Incorporated | Prevention of charge accumulation in micromirror devices through bias inversion |
| PT1592384E (pt) | 2003-01-21 | 2013-01-28 | Yeda Res & Dev | Cop-1 para o tratamento de doenças inflamatórias do intestino |
| CA2518079A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| HRP20140524T1 (hr) * | 2003-05-14 | 2014-12-19 | Teva Pharmaceutical Industries Ltd. | Kombinacijska terapija glatiramer acetatom i mitoksantronom za lijeäśenje multiple skleroze |
| EA200600877A1 (ru) | 2003-10-31 | 2006-12-29 | Тева Фармасьютикал Индастриз, Лтд. | Наночастицы для доставки лекарств |
| HUP0303779A2 (en) * | 2003-11-20 | 2006-02-28 | Richter Gedeon Vegyeszet | Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex |
| CA2558380A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| WO2005092066A2 (en) * | 2004-03-25 | 2005-10-06 | Janssen Pharmaceutica N.V. | Imidazole compounds |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| RU2410115C2 (ru) | 2004-05-07 | 2011-01-27 | Пептиммьюн, Инк. | Способы лечения заболеваний с помощью статистических сополимеров |
| WO2006004749A2 (en) * | 2004-06-25 | 2006-01-12 | Id Biomedical Corporation Of Quebec | Compositions and methods for treating neurological disorders |
| CA2579038A1 (en) * | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| KR101317131B1 (ko) | 2004-09-09 | 2013-10-10 | 테바 파마슈티컬 인더스트리즈 리미티드 | 정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법 |
| WO2006050122A1 (en) | 2004-10-29 | 2006-05-11 | Sandoz Ag | Processes for preparing glatiramer |
| WO2006083608A1 (en) | 2005-02-02 | 2006-08-10 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| US20080261894A1 (en) | 2005-02-17 | 2008-10-23 | Rivka Kreitman | Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2606194A1 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
| WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| TWI542374B (zh) | 2006-06-30 | 2016-07-21 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
| ATE452140T1 (de) | 2006-07-05 | 2010-01-15 | Momenta Pharmaceuticals Inc | Verbessertes verfahren zur herstellung von copolymer-1 |
| JP2010540634A (ja) * | 2007-10-01 | 2010-12-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | シクロホスファミドを用いて自己免疫神経疾患を処置する方法 |
| US20090149541A1 (en) | 2007-11-28 | 2009-06-11 | Yafit Stark | Method of delaying the onset of clinically definite multiple sclerosis |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| CA2697570C (en) | 2009-07-15 | 2011-11-01 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| HUE031282T2 (hu) | 2009-08-20 | 2017-06-28 | Yeda Res & Dev | Alacsony gyakoriságú glatiramer acetát terápia |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| NZ703122A (en) | 2010-10-11 | 2016-06-24 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| KR20140101730A (ko) | 2011-10-10 | 2014-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성 |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| EA201591251A1 (ru) | 2013-01-04 | 2016-05-31 | Тева Фармасьютикал Индастриз Лтд. | Характеризация лекарственного продукта, родственного ацетату глатирамера |
| EA201591687A1 (ru) | 2013-03-12 | 2016-07-29 | Тева Фармасьютикал Индастриз Лтд. | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата |
-
2010
- 2010-08-19 HU HUE15171065A patent/HUE031282T2/hu unknown
- 2010-08-19 RS RS20170053A patent/RS55607B1/sr unknown
- 2010-08-19 ES ES17157735.6T patent/ES2689711T3/es active Active
- 2010-08-19 PT PT131660805T patent/PT2630962T/pt unknown
- 2010-08-19 HR HRP20130677AT patent/HRP20130677T1/hr unknown
- 2010-08-19 BR BR112012003730-7A patent/BR112012003730A2/pt not_active Application Discontinuation
- 2010-08-19 SI SI201031375A patent/SI2949335T1/sl unknown
- 2010-08-19 CN CN201610104429.4A patent/CN105770855A/zh active Pending
- 2010-08-19 PL PL17157735T patent/PL3199172T3/pl unknown
- 2010-08-19 LT LTEP13166080.5T patent/LT2630962T/lt unknown
- 2010-08-19 WO PCT/US2010/002283 patent/WO2011022063A1/en not_active Ceased
- 2010-08-19 DK DK10810282.3T patent/DK2405749T3/da active
- 2010-08-19 SI SI201031719T patent/SI2630962T1/sl unknown
- 2010-08-19 EP EP17157735.6A patent/EP3199172B1/en not_active Revoked
- 2010-08-19 CZ CZ2015-31885U patent/CZ29723U1/cs not_active IP Right Cessation
- 2010-08-19 AT ATGM50231/2015U patent/AT15421U1/de not_active IP Right Cessation
- 2010-08-19 CA CA2876966A patent/CA2876966A1/en not_active Abandoned
- 2010-08-19 SG SG10201405806SA patent/SG10201405806SA/en unknown
- 2010-08-19 JP JP2012525530A patent/JP6038653B2/ja active Active
- 2010-08-19 PT PT108102823T patent/PT2405749E/pt unknown
- 2010-08-19 KR KR1020167006001A patent/KR20160038057A/ko not_active Ceased
- 2010-08-19 PL PL13166080T patent/PL2630962T3/pl unknown
- 2010-08-19 ES ES10810282T patent/ES2424692T3/es active Active
- 2010-08-19 DK DK15171065.4T patent/DK2949335T3/en active
- 2010-08-19 ME MEP-2013-81A patent/ME01536B/me unknown
- 2010-08-19 EP EP13166080.5A patent/EP2630962B1/en not_active Revoked
- 2010-08-19 EP EP18179172.4A patent/EP3409286B1/en not_active Revoked
- 2010-08-19 SI SI201030270T patent/SI2405749T1/sl unknown
- 2010-08-19 UA UAA201203259A patent/UA103699C2/ru unknown
- 2010-08-19 AU AU2010284666A patent/AU2010284666B2/en not_active Withdrawn - After Issue
- 2010-08-19 ME MEP-2017-17A patent/ME02662B/me unknown
- 2010-08-19 EA EA201691347A patent/EA032287B1/ru unknown
- 2010-08-19 SG SG2012011425A patent/SG178495A1/en unknown
- 2010-08-19 PL PL15171065T patent/PL2949335T3/pl unknown
- 2010-08-19 DK DK17157735.6T patent/DK3199172T3/en active
- 2010-08-19 NZ NZ598661A patent/NZ598661A/xx unknown
- 2010-08-19 PL PL10810282T patent/PL2405749T3/pl unknown
- 2010-08-19 SI SI201031740T patent/SI3199172T1/sl unknown
- 2010-08-19 HU HUE17157735A patent/HUE039335T2/hu unknown
- 2010-08-19 LT LTEP17157735.6T patent/LT3199172T/lt unknown
- 2010-08-19 ES ES13166080.5T patent/ES2688873T3/es active Active
- 2010-08-19 EA EA201270292A patent/EA019998B9/ru not_active IP Right Cessation
- 2010-08-19 KR KR1020127007115A patent/KR20120090044A/ko not_active Ceased
- 2010-08-19 EA EA201400394A patent/EA032283B1/ru unknown
- 2010-08-19 EP EP10810282.3A patent/EP2405749B1/en not_active Revoked
- 2010-08-19 EP EP15171065.4A patent/EP2949335B1/en not_active Revoked
- 2010-08-19 CN CN201610878988.0A patent/CN107050423A/zh active Pending
- 2010-08-19 MX MX2012002082A patent/MX2012002082A/es active IP Right Grant
- 2010-08-19 KR KR1020147012452A patent/KR20140061559A/ko not_active Ceased
- 2010-08-19 DE DE202010018377.4U patent/DE202010018377U1/de not_active Ceased
- 2010-08-19 LT LTEP15171065.4T patent/LT2949335T/lt unknown
- 2010-08-19 US US12/806,684 patent/US8399413B2/en not_active Expired - Fee Related
- 2010-08-19 CN CN2010800369660A patent/CN102625657A/zh active Pending
- 2010-08-19 KR KR1020177031069A patent/KR20170123354A/ko not_active Ceased
- 2010-08-19 ES ES15171065.4T patent/ES2612001T4/es active Active
- 2010-08-19 RS RS20130293A patent/RS52885B/sr unknown
- 2010-08-19 SM SM20170057T patent/SMT201700057T1/it unknown
- 2010-08-19 PT PT17157735T patent/PT3199172T/pt unknown
- 2010-08-19 DK DK13166080.5T patent/DK2630962T3/en active
- 2010-08-19 CZ CZ2016-33036U patent/CZ30474U1/cs not_active IP Right Cessation
- 2010-08-19 PT PT151710654T patent/PT2949335T/pt unknown
- 2010-08-19 CA CA2760802A patent/CA2760802C/en active Active
- 2010-08-20 TW TW106100768A patent/TW201733575A/zh unknown
- 2010-08-20 AR ARP100103062A patent/AR077896A1/es not_active Application Discontinuation
- 2010-08-20 TW TW103138861A patent/TWI643614B/zh not_active IP Right Cessation
- 2010-08-20 TW TW099128023A patent/TWI477273B/zh active
-
2011
- 2011-11-30 US US13/308,299 patent/US8232250B2/en not_active Expired - Fee Related
-
2012
- 2012-02-14 IL IL218106A patent/IL218106A0/en active IP Right Grant
-
2013
- 2013-02-19 US US13/770,677 patent/US8969302B2/en not_active Expired - Fee Related
- 2013-07-22 CY CY20131100615T patent/CY1114537T1/el unknown
-
2014
- 2014-02-26 HK HK19100376.3A patent/HK1258008A1/en unknown
- 2014-06-30 IL IL233468A patent/IL233468A0/en unknown
-
2015
- 2015-01-12 AR ARP150100073A patent/AR099078A2/es not_active Application Discontinuation
- 2015-02-24 US US14/630,326 patent/US20150164977A1/en not_active Abandoned
- 2015-03-30 US US14/673,257 patent/US9402874B2/en active Active
- 2015-05-13 JP JP2015098415A patent/JP6169644B2/ja active Active
- 2015-05-22 US US14/720,556 patent/US9155776B2/en not_active Expired - Fee Related
- 2015-12-18 SK SK50135-2015U patent/SK501352015U1/sk unknown
-
2016
- 2016-01-06 DK DK201600003U patent/DK201600003Y3/da not_active IP Right Cessation
- 2016-05-06 US US15/148,215 patent/US20160250251A1/en not_active Abandoned
- 2016-12-01 HK HK16113727.5A patent/HK1225310A1/zh unknown
- 2016-12-15 US US15/380,579 patent/US20170095523A1/en not_active Abandoned
-
2017
- 2017-01-13 HR HRP20170056TT patent/HRP20170056T2/hr unknown
- 2017-01-16 CY CY20171100052T patent/CY1118529T1/el unknown
- 2017-01-25 SM SM201700057T patent/SMT201700057B/it unknown
- 2017-02-22 JP JP2017031335A patent/JP2017132773A/ja not_active Withdrawn
- 2017-03-27 US US15/469,758 patent/US20170196803A1/en not_active Abandoned
- 2017-04-26 IL IL251943A patent/IL251943A0/en unknown
- 2017-07-05 US US15/642,201 patent/US20170296464A1/en not_active Abandoned
- 2017-11-13 US US15/811,495 patent/US20180064639A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/908,441 patent/US20180185274A1/en not_active Abandoned
- 2018-06-27 US US16/020,591 patent/US20180311149A1/en not_active Abandoned
- 2018-08-06 HR HRP20181254TT patent/HRP20181254T1/hr unknown
- 2018-08-06 HR HRP20181253TT patent/HRP20181253T1/hr unknown
- 2018-10-19 US US16/165,541 patent/US20190054013A1/en not_active Abandoned
-
2019
- 2019-02-11 US US16/272,786 patent/US20190175494A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20160038057A (ko) | 글라티라머 아세테이트를 포함하는 약제 | |
| AU2013203367B2 (en) | Low frequency glatiramer acetate therapy | |
| AU2016100455B4 (en) | Low frequency glatiramer acetate therapy | |
| AU2015101564B4 (en) | Low frequency glatiramer acetate therapy | |
| HK1234325B (en) | Dosing regimen for multiple sclerosis | |
| HK1234325A1 (en) | Dosing regimen for multiple sclerosis | |
| HK1188722A (en) | Low frequency glatiramer acetate therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20160304 Application number text: 1020147012452 Filing date: 20140508 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20160404 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20161116 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20170727 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20161116 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20171026 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20170727 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2017101005227 Request date: 20171026 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017101005227; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20171026 Effective date: 20181227 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20181227 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20171026 Decision date: 20181227 Appeal identifier: 2017101005227 |